Editorial: Statin therapy for the metabolic syndrome: The evidence base

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 5, 2009, Pages 393-396

  Jialal, Ishwarlal ^a   Devaraj, Sridevi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LIPID;

CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED PRACTICE; HUMAN; METABOLIC SYNDROME X; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; EVIDENCE BASED MEDICINE; METABOLISM; PATIENT SELECTION;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; METABOLIC SYNDROME X; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 70350342649     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0705.edi     Document Type: Editorial

References (17)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/ National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation 2005;112:2735-2752. (Pubitemid 41532612)
3. Jialal I. Editorial. Met Syndr Relat Disord 2007;5:1-2.
4. Jialal I. The role of the laboratory in the diagnosis of the metabolic syndrome. Am J Clin Pathol 2009;132:161-162.
5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Effi cacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
6. Devaraj S, Rogers J, Jialal I. Statins and biomarkers of infl ammation. Curr Athero Rpts 2007;9:33-41.
7. Wolfrum S, Liao JK. The pleiotropic effects of statins: Relevance to their salutary effects. Statins: Understanding Clinical Use. Ed: J Mehta. Philadelphia, PA: WB Saunders, 2004:163-188.
8. Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J; Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in non-diabetic CHD with and without metabolic syndrome. Diabetes Care 2004;27:1735-1740.
9. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinfl ammatory effect of simvastatin in patients with the metabolic syndrome. J Clin Endo Metab 2006;99:4489-4496.
10. Clearfi eld M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM Jr. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol 2005;96:1674-1680.
11. Towne S, Thara E. Do statins reduce events in patients with metabolic syndrome? Curr Atheroscler Rep 2008;10:39-44.
12. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-419.
13. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet 2006;368:919-928. (Pubitemid 44331360)
14. Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of infl ammation and oxidative stress in subjects with metabolic syndrome. Am Cardiol 2008;102:321-325.
15. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
16. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009;373:1175-1182.
17. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009;20;182-189.